

West Chester University Digital Commons @ West Chester University

Biology Faculty Publications

Biology

2008

Genotoxic Stress-Induced Expression of p53 and Restoration of Apoptosis in Leukemic Clam Hemocytes with Cytoplasmically Sequestered p53

Stefanie Boettger

West Chester University of Pennsylvania, sboettger@wcupa.edu

Emily Jerszyk

University of New Hampshire - Main Campus

Ben Low

University of New Hampshire - Main Campus

Charles Walker

University of New Hampshire - Main Campus

Follow this and additional works at: http://digitalcommons.wcupa.edu/bio_facpub



Part of the [Cancer Biology Commons](#), and the [Marine Biology Commons](#)

Recommended Citation

Boettger, S., Jerszyk, E., Low, B., & Walker, C. (2008). Genotoxic Stress-Induced Expression of p53 and Restoration of Apoptosis in Leukemic Clam Hemocytes with Cytoplasmically Sequestered p53. *Cancer Research*, 68, 777-782. Retrieved from http://digitalcommons.wcupa.edu/bio_facpub/18

This Article is brought to you for free and open access by the Biology at Digital Commons @ West Chester University. It has been accepted for inclusion in Biology Faculty Publications by an authorized administrator of Digital Commons @ West Chester University. For more information, please contact wcressler@wcupa.edu.

Genotoxic Stress-Induced Expression of p53 and Apoptosis in Leukemic Clam Hemocytes with Cytoplasmically Sequestered p53¹.

by

Stefanie Böttger, Emily Jerszyk, Ben Low and Charles Walker

Department of Zoology, Center for Marine Biology and Marine Biomedical Research Group,
Rudman Hall, University of New Hampshire, Durham, NH 03824

Running Title. Overcoming Cytoplasmic Sequestration of p53.

Key Words. Cytoplasmic sequestration, p53, topoisomerase poisons, mortalin,
genotoxic stress.

1 **Request for reprints:** Charles Walker, Department of Zoology, Center for Marine Biology and Marine Biomedical Research Group, The University of New Hampshire, Durham, New Hampshire 03824. Phone: 603-862-2111; Fax: 603-862-3784; E-mail: cwwalker@christa.unh.edu.

Abstract

In nature the soft shell clam, *Mya arenaria*, develops a fatal blood cancer in which a highly conserved homolog for wild type human p53 protein is rendered non-functional by cytoplasmic sequestration. In untreated leukemic clam hemocytes, p53 is complexed throughout the cytoplasm with over-expressed variants for both clam homologs (full-length variant - 1200-fold and truncated variant - 620-fold above normal clam hemocytes) of human mortalin, an Hsp70 family protein. *In vitro* treatment with etoposide only and *in vivo* treatment with either etoposide or mitoxantrone induces DNA damage, elevates expression (600-fold) and promotes nuclear translocation of p53 and results in apoptosis of leukemic clam hemocytes. Pretreatment with wheat germ agglutinin followed by etoposide treatment induces DNA damage and elevates p53 expression (893-fold), but does not overcome cytoplasmic sequestration of p53 or induce apoptosis. We show that leukemic clam hemocytes have an intact p53 pathway and that maintenance of this tumor phenotype requires nuclear absence of p53 resulting from its localization in the cytoplasm of leukemic clam hemocytes. The effects of these topoisomerase II poisons may result as mortalin-based cytoplasmic tethering is overwhelmed by *de novo* expression of p53 protein following DNA-damage induced by genotoxic stress. Soft shell clam leukemia provides excellent *in vivo* and *in vitro* models for developing genotoxic and non-genotoxic cancer therapies for reactivating p53 transcription in human and other animal cancers displaying mortalin-based cytoplasmic sequestration of the p53 tumor suppressor (currently - colorectal cancers and primary and secondary glioblastomas and not apparently leukemias or lymphomas).

Introduction

In normal mammalian cells, p53 suppresses the formation of tumors by arresting the cell cycle or by apoptosis in response to genotoxic stress induced DNA damage (1). Levels and activity of p53 increase in response to DNA damaging agents (2-4). Transcription of p53-regulated genes yields proteins that can edit and repair DNA and/or promote apoptosis based on the degree of DNA damage. Loss of cell cycle control results upon inactivation of p53 and loss of p53 transcriptional activity and can lead to development and progression of tumors (1). Non-transcriptional induction of apoptosis can also occur through binding of mitochondrially-directed p53 and inactivation of Bcl2 or other anti-apoptotic proteins (5, 6).

In this study, we use genotoxic stress induced DNA damage to promote expression and to reverse cytoplasmic sequestration of p53 and to restore its apoptotic function in a naturally occurring diffuse tumor of the hemocytes of the soft shell clam. In leukemic clam hemocytes, a highly conserved clam homolog for human p53 (Map53, GenBank accession number AF253323) is rendered non-functional by sequestration in the cytoplasm by both variants of the clam homolog for human mortalin (*Mya arenaria* mortalin - full length & truncated, GenBank Accession numbers AY326398 & EF576660, respectively) (7, 8). Truncated clam mortalin is missing exon 2 that includes the ATP-binding and ATPase domain required to reverse p53 binding. We hypothesize that normal transcriptional functions of p53 in tumor suppression are silenced when clam mortalin proteins are over-expressed. For instance, transcriptionally controlled editing and repair of DNA and induction of apoptosis would not be initiated by p53 that cannot enter the nucleus, bind DNA and direct the expression of relevant genes. Similarly, ubiquitination dictated by Mdm2 binding to the TAD of p53 or by CIP1 down regulation of G1

cyclin/CDK dependent phosphorylation and activation of p53 cannot occur. Cytoplasmic sequestered p53 might still direct non-transcriptional initiation of apoptosis at the mitochondria if mortalin binding does not interfere with this pathway (9).

While cytoplasmic sequestration has not yet been recorded for human leukemias or lymphomas, a subset of naturally occurring but unrelated human cancers do retain p53 in the cytoplasm (e.g., undifferentiated neuroblastoma, breast, retinoblastoma, colorectal adenocarcinomas and glioblastoma (10-12) and this phenotype can be induced in mouse NIH 3T3 and human HeLa cells (13-16). In all of these cases, wild type p53 is inactivated because it is retained in the cytoplasm. A variety of molecular mechanisms have been linked to cytoplasmic sequestration in these human cancers, e.g., truncation of the nuclear localization motif receptor protein, importin α (17); overactive nuclear export by an Mdm2 dependent pathway (18) and cytoplasmic tethering by foreign (viral) (19) or local cytoplasmic proteins (9, 15, 20). In human colorectal cancer cells and leukemic clam hemocytes, mortalin is responsible for cytoplasmic tethering when the latter protein is over-expressed (8, 21). Dundas et al indicate that high levels of mortalin expression are correlated with poor clinical outcome for colorectal cancer. A recent study of primary and secondary glioblastomas suggests that mortalin and/or other tethering molecules (e.g., cullin 7 or PARC) may be also be responsible for cytoplasmic sequestration in these cancers (12).

In the current study we use leukemic clam hemocytes for *in vitro* and *in vivo* assays to evaluate cytotoxicity, intracellular localization of p53, DNA damage and apoptosis following treatment with two genotoxic DNA topoisomerase II poisons, etoposide and mitoxantrone. Since we were investigating a blood disease in the clam, these topoisomerase II poisons were originally chosen from the standard agent database at the National Cancer Institute because they are highly

cytotoxic to human lymphoblastic leukemia cell lines (22) and have demonstrated effectiveness against human leukemias and lymphomas (www.dtp.nci.nih.gov/docs/compare/examples/topoii.html). Importantly these topoisomerase II poisons do have significant genotoxic effects on a variety of human cancers, but have never been evaluated in terms of their effects on cancers resulting from mortalin-based cytoplasmic sequestration.

Understanding the molecular basis for this negative regulatory pathway for p53 might lead to therapies for any human cancer where cytoplasmic sequestration is mediated by mortalin. As Martins et al (23) point out, “reinstatement of p53 function is an attractive tumor-specific therapeutic strategy, but it will only work if tumors harbor persistent p53-activating signals that engage growth inhibition or death.” In the present study, we show that clam leukemia cells have an intact p53-activating pathway leading to apoptosis and that maintenance of this diffuse tumor requires nuclear absence of p53 dictated by its localization in the cytoplasm.

Materials and Methods

Clams. Soft shell clams (*Mya arenaria*, $n \approx 150-200$) were collected at the lowest tides of each month from sand flats on Marsh Island in New Bedford Harbor at Fairhaven, Massachusetts (41° 38.0' N 70° 55.0' W) and were maintained at the UNH Coastal Marine Laboratory, New Castle, New Hampshire. For biopsy, a small aliquot of hemolymph (10 μ l) was removed from the pericardial sinus and incubated for 2 hours at 8°C. Clams were classified with a Zeiss IM inverted microscope as normal (zero % round, non-motile leukemic clam hemocytes; 100% attached normal clam hemocytes), early incipient leukemic (1-50% leukemic clam hemocytes), late incipient leukemic (50-99% leukemic clam hemocytes) or fully leukemic (100% leukemic

clam hemocytes). In 51 collections made over a 5yr period the average number of clams that was 100% leukemic was 5.64%; the range was 0-11%. Only fully leukemic clams were used for the experiments presented in this study.

Antibody for p53. A polyclonal antibody to *Mya arenaria* p53 protein (Map53 rabbit anti-clam polyclonal) was raised against a peptide synthesized from a highly immunogenic region in the core sequence of clam p53 and including part of DNA binding domain V (Map53 23-mer CACPGRDRKADERGSLPPMVSGG). The polyclonal antibody obtained was successfully screened for its ability to recognize clam p53 in Western blot analysis of both *in vitro* expressed clam proteins and whole cell extracts collected *in vivo* from leukemic and normal clam hemocytes (7).

Treatment of Leukemic Clam Hemocytes with leptomycin B (LMB) *in vitro*. In order to determine if overactive nuclear export is responsible for cytoplasmic sequestration of p53, leukemic clam hemocytes were treated with LMB which blocks CRM1-mediated nuclear export. Hemolymph was removed from the pericardial sinus of fully leukemic (100%) clams. Blood was divided into eight tubes for time zero, 4, 8, and 24 hrs with two treatments per time (control and LMB treatment). LMB treatments only received a final concentration of 115 nM LMB, control treatments received normal clam medium without the drug. All tubes were maintained on a rotator at 8°C for the required length of time. At each time point (time zero 4, 8 and 24 hrs) nuclear and cytoplasmic protein extractions (NEPER, Pierce) were performed and clam p53 distribution was determined using western blotting.

Treatment of Leukemic Clam Hemocytes with Topoisomerase II Poisons *in vitro*. Hemolymph was removed from the pericardial sinus of fully leukemic (100%) clams and was diluted with clam culture medium (24) to 4×10^5 leukemic clam hemocytes ml^{-1} . Hemolymph

and topoisomerase II poisons (0-0.07 mM mitoxantrone and 0-0.1 mM etoposide) were diluted with clam culture medium to a final concentration of 1×10^5 leukemic clam hemocytes ml^{-1} in 1.5 ml microcentrifuge tubes (Fisher Scientific). Samples of 400 μl were removed at time zero, 6 and 18 hours; *In vivo* - To approximate drug concentrations used *in vitro* (0.07 mM mitoxantrone and 0.075 mM etoposide), hemolymph volumes were estimated based on clam shell size and the appropriate concentrations of drugs were injected immediately following the zero time biopsy. Additional biopsies were performed at 8, 20 and 24 h on 800 μl of hemolymph removed from the pericardial sinus.

Pretreatment of Leukemic Clam Hemocytes with wheat germ agglutinin (WGA) *in vitro*. To evaluate mechanism of action of p53 and detect any alternative routes leading to apoptosis, we set up four treatments, leukemic clam hemocytes untreated, leukemic clam hemocytes treated with WGA only, leukemic clam hemocytes treated with 0.075 mM etoposide only and leukemic clam hemocytes pre-treated with WGA followed by exposure to 0.075 mM etoposide. Pre-treatment of leukemic clam hemocytes with WGA was conducted using FITC-labeled WGA (Sigma) that was transfected into the cells using the Chariot protein delivery system (Active Motif). WGA was allowed to couple with the Chariot compound for 30 minutes at room temperature to form complexes that were incubated for 1 hr with leukemic clam hemocytes suspended in clam culture medium at concentrations of 6×10^5 hemocytes/100 μl medium. Successful transfection of WGA into leukemic clam hemocytes results in blockage of the nuclear pores and translocation of p53 into the nucleus should also be blocked. *De novo* or unbound p53 should be directed to mitochondria resulting in non-transcriptional induction of apoptosis. Following transfection, all treatments (control and etoposide treated) were allowed to

incubate for 6 hrs, nuclear and cytoplasmic proteins separated (NEPER, Pierce) and clam p53 distribution determined using western blotting.

Cytotoxicity Assay. Prior to *in vitro* and *in vivo* drug treatments lactate dehydrogenase activity (LDH) was measured (Promega, CytoTox 96® Non-Radioactive Cytotoxicity Assay G1780) using increasing numbers of leukemic clam hemocytes (0-140,000 cells) to test the validity of this assay in the clam model, determine the numbers of leukemic clam hemocytes needed and adjust environmental conditions (e.g. temperature). Once these parameters were determined, we followed the procedure and analyses described by Promega and utilized in over 350 published studies.

Immunocytochemistry. Cytospins of 100 µl of leukemic clam hemocytes from untreated and treated individuals *in vitro* and *in vivo* were fixed and permeabilized by immersion in acetone. These preparations were treated with the clam p53 primary antibody (7). Resulting preparations were developed with a peroxidase labeled secondary antibody (Vectastain ABC Elite IgG kit, Vector Laboratories). Control cytopins received identical treatment in the absence of primary antibody. After completing the assay, fields of 200 leukemic clam hemocytes were counted and scored into three categories: a) cells with predominantly nuclear clam p53, b) cells with predominantly cytoplasmic clam p53 and c) cells where the intracellular distribution of clam p53 was indeterminate. The non-parametric Wilcoxon-Mann-Whitney test was applied to assess differences between results in categories a-c and between time-points.

Western Blotting. To determine the cellular localization of p53 protein, nuclear and cytoplasmic proteins were extracted from 200µl of hemolymph containing leukemic clam hemocytes at each time point during treatment with mitoxantrone and etoposide using NE-PER (nuclear and cytoplasmic extraction reagents, Pierce). Total protein was measured

spectrophotometrically (Ultraspec 3100) using a modified Lowry procedure (Bio-Rad protein assay). Nuclear and cytoplasmic proteins (37.5 µg) were assayed by western blotting on 4-15% Tris-HCl Ready gels (Bio-Rad) transferred to a PVDF membrane (Bio-Rad), treated with the clam p53 primary antibody and visualized colorimetrically (7).

Comet Assay. To detect DNA damage during *in vitro* and *in vivo* drug treatments with topoisomerase II agents (measured as DNA fragmentation and observed as a comet-shaped tail discharged from the nucleus) COMET assays were performed at each time point (Trevigen CometAssay™ kit, 4250-050). Results were scored as percent of DNA damaged cells in a total of 100 cells.

Apoptosis Assays. To document apoptosis, Romanovsky staining (ThermoShandon, Kwik™ Diff Stain Kit) and the TUNEL assay (*In situ* cell death detection kit, AP, Roche) were performed on cytopins of leukemic clam hemocytes at 6 hrs *in vitro* and 8 hrs *in vivo*. Following staining, hemocytes were mounted under coverslips with Permount (for Romanovsky, Fisher Scientific) or with Vectashield (for TUNEL, Vector Laboratories) and scored at 600x on a Zeiss Axioplan II microscope (Carl Zeiss, Inc., Thornwood, N.J.) (25). For the Romanovsky assay, cells were designated as apoptotic when intracellular vacuoles were observed and apoptosis was expressed as a percentage in a total of 100 cells. For the TUNEL assay results were scored as percentage of apoptotic cells (TUNEL positive cells) out of total of 100 cells.

Quantitative PCR (QPCR). To document expression of mortalin and p53, 500 µl of hemolymph were removed from normal, leukemic and 0.075 mM etoposide treated leukemic clams (with and without prior treatment with WGA). The hemolymph was centrifuged at 3,000g for 10 min, RNA extracted using Trizol (Invitrogen) and cDNA synthesized using SuperScript™ First-Strand Synthesis System (Invitrogen). All samples were prepared for QPCR using the

Taqman ® Fast System (Applied Biosystems) and run in a 7500 Fast RT-PCR System (Applied Biosystems) at 45 cycles of 95°C with automatically set Ct.

Results

Treatment with 115 nM of the nuclear export blocker leptomycin B for 8 and 24 hours did not result in localization of p53 in the nucleus, suggesting that overactive nuclear export of p53 mediated by CRM1 is not responsible for cytoplasmic sequestration in leukemic clam hemocytes (**results not shown**).

LDH activity decreased for leukemic clam hemocytes treated with etoposide at 6 hrs *in vitro* (0-0.1 mM etoposide) and 8 hrs *in vivo* (0.075 mM etoposide only; $p < 0.001$) indicating increased cytotoxicity (ANOVA on arcsine transformed data, **Fig. 1**). LDH activity increased at 18 hrs of treatment *in vitro* (0-0.1 mM etoposide) and 20-24 hr treatment *in vivo* (0.075 mM etoposide only) using etoposide and indicating decreased cytotoxicity. Treatment of leukemic clam hemocytes for 8 hrs with mitoxantrone *in vivo* (0.07 mM mitoxantrone) resulted in increased cytotoxicity. Following treatment for 20 hrs cytotoxicity decreased, followed by an increase at 24 hrs of treatment. *In vitro* treatment with mitoxantrone (0-0.07 mM mitoxantrone) resulted no changes in these parameters ($p = 0.087$).

Nuclear clam p53 increased following treatment with 0.07 mM mitoxantrone *in vivo* ($p = 0.047$) while *in vitro* treatment with this drug had no effect (Kruskal-Wallis followed by Bonferroni test, **Fig. 2**). Both *in vitro* and *in vivo* treatments with etoposide (0.075 mM) resulted in increased nuclear clam p53. This result was most pronounced during *in vivo* treatment.

Following treatment of leukemic clam hemocytes with etoposide *in vitro* and *in vivo*, the Comet assay indicated increased DNA fragmentation, while treatment with mitoxantrone yielded

DNA fragmentation *in vivo* only (Mann-Whitney-test, **Fig. 3A and B**). DNA fragmentation was notably higher in leukemic clam hemocytes treated with etoposide *in vitro*. Following treatment with mitoxantrone and etoposide, apoptotic leukemic clam hemocytes increased both *in vitro* and *in vivo*. However, apoptosis occurred less frequently following treatment with mitoxantrone than following treatment with etoposide (Mann-Whitney-test, **Fig. 3 C and D**). Percentages of apoptotic leukemic clam hemocytes were significantly lower when assessed by observations of Romanovsky stained cells than by the TUNEL assay. Analysis by Romanovsky staining detects apoptosis at a later stage when leukemic clam hemocytes are forming internal vesicles; the more sensitive TUNEL assay provides a quantitative estimate of apoptotic DNA damage at an earlier stage and yields a significantly higher estimate for apoptotic leukemic clam hemocytes.

After transfection of leukemic clam hemocytes with the nuclear pore blocker wheat germ agglutinin followed by etoposide treatment, p53 was found only in the cytoplasm of leukemic clam hemocytes and was not transported into the nucleus and no increase in apoptotic cells was noted (**results not shown**). Frequencies of apoptotic cells were lower in leukemic clam hemocytes pre-treated with WGA (15.3%) than in hemocytes treated directly with 0.075 mM etoposide (74.4%).

Expression of p53 did not differ between untreated normal and leukemic clam hemocytes. In leukemic clam hemocytes treated with etoposide, p53 was over-expressed 602 fold compared to untreated leukemic hemocytes, which showed higher expression than normal clam hemocytes by 30% (**Table 1**). When transfected with the nuclear pore blocker wheat germ agglutinin, followed by treatment with etoposide, p53 was over-expressed 893 fold compared to untreated normal clam hemocytes. Expression of mortalin differed between normal and leukemic clam hemocytes by 1634 and 619 times for the long and short versions respectively. Additional

increase of mortalin expression was observed in leukemic clam hemocytes treated with etoposide by 204 fold for the long variant and 159 fold for the short variant.

Discussion

Non-genotoxic and genotoxic strategies for reactivating p53 function are of high interest since they may lead to promising cancer therapies (23, 26-28). Based on an understanding of the normal p53 mediated pathway for suppressing cancer induction, strategies for reactivating p53 have been proposed. Among others these include: stabilizing p53 using small molecule Mdm2 antagonists (e.g., nutlins) (29-32) and inducing *de novo* expression of p53 following DNA damage resulting from genotoxic stress or gene therapy (33-35).

Previous studies in humans and clams have shown that the cationic inhibitor of mortalin, MKT-077 competes with mortalin for p53 binding and results in translocation of p53 to the nucleus followed by rapid apoptosis (8, 36, 37). Use of this small molecule does not induce DNA-damage or elevate transcription of p53.

In the present study, we utilize genotoxic stress to promote transcription of *de novo* wild type p53, translocation of p53 to the nucleus and apoptosis of leukemic clam hemocytes. The apoptotic outcome can be prevented following transfection with the nuclear pore blocker wheat germ agglutinin. **While cytoplasmic sequestration of p53 occurs in a variety of human cancers, no one has previously linked treatment with these topoisomerase II poisons to reversal of mortalin-based cytoplasmic sequestration and apoptotic death of cancer cells in any organism.**

Mortalin is a member of the Hsp70 family of proteins that is not upregulated by heat. In mammals, it functions in mitochondrial import, energy generation, chaperoning of misfolded

proteins, as a stress sensor and is involved in carcinogenesis and old age disorders (e.g., Parkinson's, Alzheimer's and Huntington's diseases) (9). We have identified two variants of mortalin in the clam, a full length and a truncated variant. Both contain an N-terminal mitochondrial localization signal and a p53 binding site, but the truncated variant is missing amino acids represented by exon 2, which contain ATP binding and ATPase functions, necessary for releasing p53 from binding. Both variants are complexed in the cytoplasm of leukemic clam hemocytes with p53. At this point it is unclear if either over-expressed variant is exclusively responsible for sequestering p53 in the cytoplasm of leukemic clam hemocytes. While both variants of mortalin are also minimally upregulated following treatment with etoposide, mortalin-based cytoplasmic tethering mechanism is apparently still overwhelmed, allowing nuclear translocation of untethered clam p53.

Etoposide forms a complex between DNA and DNA topoisomerase II resulting in decreased DNA religation and strand breaks (38); secondary cancers can result (39, 40). Over-expression of wild type p53 facilitates etoposide induced death of cancer cells in human colon carcinoma cell lines (HCT116 and RKO) (3). In the current study, treatment of leukemic clam hemocytes with etoposide resulted in DNA damage and increased expression of clam p53 followed by nuclear translocation of some p53 and apoptosis.

Mitoxantrone causes crosslinking and DNA strand breaks and interferes with the function of DNA topoisomerase II and with DNA repair. Mitoxantrone kills both proliferating and nonproliferating cells. (41,42). In the current study, mitoxantrone was minimally effective at reversing cytoplasmic sequestration of clam p53 *in vivo* and had no obvious effects *in vitro*. Discrepancies between data acquired *in vivo* and *in vitro* for mammalian cells derived from the same source tissues are common in preclinical pharmacokinetic studies (22).

The most attractive interpretation of our data is that treatment with etoposide and mitoxantrone poisons elevates p53 levels in the cytoplasm of leukemic clam hemocytes and that *de novo* p53 protein overwhelms mortalin-tethering resulting in nuclear translocation of some p53 followed by cytotoxicity, DNA damage and apoptosis of leukemic clam hemocytes. Upon entering the nucleus following etoposide or mitoxantrone treatment, *de novo* clam p53 may be phosphorylated and stabilized by ATM that senses DNA damaged induced by these drugs (43). Such stabilization would effectively increase the intranuclear concentration of p53 since Mdm2 could not bind p53 at its TAD and p53 would not be subject to Mdm2-induced ubiquitination and digestion by 26S proteasomes (44). Mdm2 levels may be low or non-existent anyway since cytoplasmically sequestered p53 was not originally present in the nucleus to induce transcription of this gene. Following treatment with topoisomerase II poisons, other proteins upregulated by p53 mediated transcription would be active in evaluating and repairing DNA or, failing that, in inducing apoptosis of leukemic clam hemocytes with severely damaged DNA. This condition would simplify the p53 mediated response, leading to the rapid apoptosis of leukemic clam hemocytes that we have observed. We saw limited evidence (15%) for transcription-independent initiation of apoptosis via transport to the mitochondria when cells were treated with wheat germ agglutinin followed by etoposide (45). Under these conditions, it is likely that, *de novo* p53 mRNA is retained in the nucleus and that additional p53 protein is not produced (46). Finally, when mortalin is overexpressed and tethers p53 in the cytoplasm of leukemic clam hemocytes, the interaction of p53 with BCL2 or other antiapoptotic molecules at the mitochondria may be restricted or absent, curtailing or preventing this alternative apoptotic induction pathway (9, 47).

Acknowledgments

July 17, 2007

Grant support: National Cancer Institute grants (CA71008-01 and CA104112-01) and Hatch (353) to CWW and a Pfizer SURF award to ECJ. Initial studies treating leukemic clam hemocytes with etoposide were accomplished by Ben Low, Jennifer Currier and Allison Kelleher who were undergraduate or graduate students in the Walker laboratory.

References

1. Clifford B, Beljin M, Stark GR, Taylor WR. G2 arrest in response to topoisomerase II inhibitors: the role of p53. *Cancer Res* 2003;63:4074-81.
2. Lutzker SG, Levine AJ. Apoptosis and cancer chemotherapy. *Cancer Treat Res* 1996;87:345-56.
3. Blagosklonny MV, El-Deiry WS. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. *International journal of cancer* 1998;75:933-40.
4. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. *J Biol Chem* 2002;277:16547-52.
5. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. *Current opinion in cell biology* 2005;17:631-6.
6. Arima Y, Nitta M, Kuninaka S, *et al.* Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. *J Biol Chem* 2005;280:19166-76.
7. Kelley ML, Winge P, Heaney JD, *et al.* Expression of homologues for p53 and p73 in the softshell clam (*Mya arenaria*), a naturally-occurring model for human cancer. *Oncogene* 2001;20:748-58.
8. Walker C, Böttger S, Low B. Mortalin-based cytoplasmic sequestration of p53 in a non-mammalian cancer model. *Am J Path* 2006;168:1526-30.
9. Kaul SC, Deocaris CC, Wadhwa R. Three faces of mortalin: A housekeeper, guardian and killer. *Experimental gerontology* 2007;42:263-74.
10. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. *Proc Natl Acad Sci U S A* 1992;89:7262-6.
11. Moll UM, LaQuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. *Proc Natl Acad Sci U S A* 1995;92:4407-11.
12. Nagpal J, Jamoona A, Gulati ND, *et al.* Revisiting the role of p53 in primary and secondary glioblastomas. *Anticancer research* 2006;26:4633-9.
13. Wadhwa R, Taira K, Kaul SC. An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? *Cell stress & chaperones* 2002;7:309-16.
14. Kaul SC, Duncan E, Sugihara T, Reddel RR, Mitsui Y, Wadhwa R. Structurally and functionally distinct mouse hsp70 family members Mot-1 and Mot-2 proteins are encoded by two alleles. *DNA Res* 2000;7:229-31.
15. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. *Cell* 2003;112:29-40.
16. Kuperwasser C, Pinkas J, Hurlbut GD, Naber SP, Jerry DJ. Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. *Cancer Res* 2000;60:2723-9.
17. Kim IS, Kim DH, Han SM, *et al.* Truncated form of importin alpha identified in breast cancer cell inhibits nuclear import of p53. *J Biol Chem* 2000;275:23139-45.
18. Rodriguez-Lopez AM, Xenaki D, Eden TO, Hickman JA, Chresta CM. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. *Molecular pharmacology* 2001;59:135-43.
19. Zhao LY, Liao D. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. *J Virol* 2003;77:13171-81.
20. Wadhwa R, Takano S, Robert M, *et al.* Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. *J Biol Chem* 1998;273:29586-91.
21. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. *J Pathol* 2005;205:74-81.
22. O'Connor PM, Jackman J, Bae I, *et al.* Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. *Cancer Res* 1997;57:4285-300.
23. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. *Cell* 2006;127:1323-34.
24. Sible J, Marsh AG, Walker CW. Effect of extrinsic polyamines on post-spawning testes of the sea star, (*Asterias vulgaris*) (Echinodermata): implications for seasonal regulation of spermatogenesis. *Invertebrate Reproduction and Development* 1992;19:257-65.
25. Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. *Nat Cell Biol* 2000;2:569-73.

26. Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V. Classic and novel roles of p53: prospects for anticancer therapy. *Trends Mol Med* 2007;13:192-9.
27. Marx J. Oncology. Recruiting the cell's own guardian for cancer therapy. *Science* (New York, NY) 2007;315:1211-3.
28. Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. *Drug Resist Updat* 2006;9:19-25.
29. Tovar C, Rosinski J, Filipovic Z, *et al.* Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. *Proc Natl Acad Sci U S A* 2006;103:1888-93.
30. Vousden KH, Lane DP. p53 in health and disease. *Nature reviews* 2007;8:275-83.
31. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. *Current cancer drug targets* 2005;5:57-68.
32. Chene P. Inhibition of the p53-hdm2 interaction with low molecular weight compounds. *Cell cycle* (Georgetown, Tex) 2004;3:460-1.
33. Mistry AR, Felix CA, Whitmarsh RJ, *et al.* DNA topoisomerase II in therapy-related acute promyelocytic leukemia. *The New England journal of medicine* 2005;352:1529-38.
34. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. *European journal of biochemistry / FEBS* 2001;268:2764-72.
35. Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. *Head & neck* 2007;29:272-84.
36. Wadhwa R, Sugihara T, Yoshida A, *et al.* Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. *Cancer Res* 2000;60:6818-21.
37. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. *Experimental cell research* 2002;274:246-53.
38. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. *Biochimica et biophysica acta* 1998;1400:233-55.
39. Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. *Cancer Res* 1993;53:2212-6.
40. Knippschild U, Milne DM, Campbell LE, *et al.* p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. *Oncogene* 1997;15:1727-36.
41. Fox EJ. Mechanism of action of mitoxantrone. *Neurology* 2004;63:15-8.
42. De Isabella P, Palumbo M, Sissi C, *et al.* Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. *Molecular pharmacology* 1995;48:30-8.
43. Xie G, Habbersett RC, Jia Y, *et al.* Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints. *Oncogene* 1998;16:721-36.
44. Zaika A, Marchenko N, Moll UM. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. *J Biol Chem* 1999;274:27474-80.
45. Zhao Y, Chaiswing L, Velez JM, *et al.* p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. *Cancer Res* 2005;65:3745-50.
46. Kehlenbach RH. In vitro analysis of nuclear mRNA export using molecular beacons for target detection. *Nucleic acids research* 2003;31:e64.
47. Wadhwa R, Taira K, Kaul SC. Can mortalin be a candidate target for cancer therapy? *Cancer Therapy* 2003;1:173-8.
48. Geyer RK, Nagasawa H, Little JB, Maki CG. Role and regulation of p53 during an ultraviolet radiation-induced G1 cell cycle arrest. *Cell Growth Differ* 2000;11:149-56.

Tables

Table 1 Quantitative PCR results (%) for cDNA from leukemic clam hemocytes, leukemic clam hemocytes transfected with the nuclear pore blocker wheat germ agglutinin (WGA) followed by 10 hr treatment with 0.075 mM etoposide. All results were normalized against Ct values from normal clam hemocytes, assuming that Ct values from normal clam hemocytes were the baseline; LCH = leukemic clam hemocytes, Etopo = etoposide, WGA = wheat germ agglutinin, mortalin LV = long variant of mortalin, mortalin SV = short variant of mortalin.

| | p53 expression | mortalin LV expression | mortalin SV expression |
|--------------------------|-----------------------|-------------------------------|-------------------------------|
| LCH | 47.0 | 1633.6 | 619.0 |
| LCH + Etopo | 602.1 | 1837.9 | 778.1 |
| LCH + WGA + Etopo | 893.8 | | |

Figure Legends

Fig.1 Cytotoxicity of Leukemic Clam Hemocytes

Lactate dehydrogenase activity (% LDH) measured cell proliferation of leukemic clam hemocytes following treatment with **A)** mitoxantrone (0-0.07 mM) *in vitro*; **B)** etoposide (0-0.1 mM) *in vitro* and **C)** mitoxantrone (0.07 mM) and etoposide (0.075 mM) *in vivo*. Cytotoxicity of leukemic clam hemocytes was expressed as % and determined using media background absorbance, untreated cell absorbance, treated cell absorbance (termed experimental release) and maximal lysed cell absorbance (termed target maximum release).

Fig. 2 Localization of Clam p53 within Leukemic Clam Hemocytes Using Immunocytochemistry

Distribution (%) of nuclear and cytoplasmic clam p53 in leukemic clam hemocytes: **A)** with mitoxantrone (0-0.07 mM) and etoposide (0-0.75 mM) *in vitro* and **B)** with mitoxantrone (0.07 mM) and etoposide (0.075 mM) *in vivo*. Results for clam p53 distribution for a total of 200 leukemic clam hemocytes are subdivided into three different scoring categories: leukemic clam hemocytes with predominantly nuclear clam p53, leukemic clam hemocytes with predominantly cytoplasmic clam 53 and leukemic clam hemocytes where the intracellular distribution of clam p53 was undetermined, Map53 = clam p53 (48).

Fig. 3 DNA Fragmentation and Apoptosis Assays of Leukemic Clam Hemocytes

Frequency of DNA damaged cells (Comet Assay; %) of leukemic clam hemocytes following treatment with mitoxantrone **A)** and etoposide **B)** Results were determined by migration of denatured and cleaved DNA fragments in 100 cells (“comet tails”) indicative of DNA damage.

July 17, 2007

Large graphs show results *in vitro*, while insets display *in vivo* experimental data and frequency of apoptotic cells in leukemic clam hemocytes treated with mitoxantrone and etoposide using **C)** Romanovsky stain and **D)** TUNEL assay as detection methods; apoptosis was determined by the development of intracellular vacuoles and the degree of nuclear fluorescence respectively. Analysis by Romanovsky staining detects apoptosis at a much later stage when leukemic clam hemocytes are forming internal vesicles and is qualitative; the more sensitive TUNEL assay provides a quantitative estimate of DNA damage at an earlier stage of apoptosis and thus detects a greater number of apoptotic leukemic clam hemocytes. Both results were expressed as a percentage of 100 cells counted.




Fig. 1








Fig. 2



■ Time zero
 ▨ 6 hrs
 □ 18 hrs

■ *in vitro* (6 hr)
 ▨ *in vivo* (8 hr)

Fig. 3